U-shaped Kirschner wire internal fixation safe and effective treatment for Skier’s thumb: Study

U-shaped Kirschner wire internal fixation safe and effective treatment for Skier’s Thumb suggests a new study published in the BMC Surgery.

Skier’s thumb is a type of injury to the ulnar collateral ligament of the metacarpophalangeal joint of the thumb, which can result in bone fragmentation and joint instability. The objective of this study was to compare the traditional Kirschner wire fixation method with the U-shaped Kirschner wire method for treating small bone fragments with displacement, rotation, or instability in skier’s fractures. A retrospective study was conducted on 30 patients with skier’s thumb who were treated at Tianjin Hospital from January 2019 to December 2021. Patients were divided into two groups: Group A received traditional Kirschner wire fixation, while Group B received U-shaped Kirschner wire fixation. Functional assessments and complications during the perioperative period were evaluated. Results: Both surgical methods significantly reduced postoperative pain and increased joint range of motion. Group B had a lower incidence of pain during follow-up and showed significant functional improvement in Tip-pinch and Grip tests compared to Group A. U-shaped Kirschner wire fixation significantly reduced complications during the perioperative period. The U-shaped Kirschner wire internal fixation is a safe and effective treatment for the thumb proximal phalanx base ulnar side avulsion fracture.

Reference:

Ma, S., Zuo, J. & Hu, Y. U-shaped kirschner wire transfixation: effective treatment for Skier’s thumb. BMC Surg 24, 91 (2024). https://doi.org/10.1186/s12893-024-02382-7

Keywords:

U-shaped, Kirschner wire, internal fixation, safe and effective, treatment

Skier’s thumb, BMC Surgery, U-shaped Kirschner wire, Ulnar collateral ligament, Metacarpophalangeal joint, Bone fragmentation

Powered by WPeMatico

Canadian study finds physician work hours, especially for male doctors, have declined since 1987

Physicians in Canada, especially male physicians, are working fewer hours than they did three decades ago, and these long-term trends must be considered in workforce planning, according to new research in CMAJ (Canadian Medical Association Journal).

Powered by WPeMatico

A primer on recent measles outbreaks, transmission, symptoms and complications, including ‘immune amnesia’

Canada is seeing a resurgence of measles, with cases in the first quarter of 2024 already far surpassing the total for all of 2023. There were 12 cases last year, and more than three times that number so far in 2024, with 38 reported as of March 19.

Powered by WPeMatico

Bypassing oral immunotherapy buildup safe in children with food allergy

An initial phase of multifood sublingual immunotherapy (SLIT) that bypasses oral immunotherapy (OIT) buildup is safe and effective, according to a study published online Feb. 27 in the Journal of Allergy and Clinical Immunology: In Practice.

Powered by WPeMatico

Race is on to make Paris Olympics mosquito-free

France is scrambling to make sure that that virus-carrying tiger mosquitos, a growing menace in Europe, don’t spoil the Paris Olympics for athletes and fans, with millions of visitors due in the French capital for the summer Games.

Powered by WPeMatico

Mifepristone access is coming before the US Supreme Court. How safe is this abortion pill?

The U.S. Supreme Court will take up a case Tuesday that could impact how women get access to mifepristone, one of the two pills used in the most common type of abortion in the nation.

Powered by WPeMatico

AIIMS Announces Time Table for Final MBBS Supplementary Professional Exams, details

New Delhi- Through a recent notice, the All India Institute of Medical Sciences (AIIMS) has released the schedule of the final MBBS supplementary professional examinations which will take place in May 2024.

The theory examination will commence from 1st to 14th May 2024 between 02:00 PM and 05:00 PM at the Examination Section on the 1st Floor of the Convergence Block at AIIMS, New Delhi. Practical examinations, on the other hand, will be held from May 16th to May 21st, 2024. Candidates are advised to refer to their respective departments for the timing and venue of the practical exams.

THEORY SCHEDULE

Date

Day

Subject

Paper No.

Venue of Theory

Time of Theory

01.05.2024

Wednesday

Obstetrics & Gynecology

I

Examination Section First Floor

Convergence Block AIIMS, New Delhi

02:00 PM to 05:00 PM

03.05.2024

Friday

Paediatrics

I

06.05.2024

Monday

Community Medicine

I

07.05.2024

Tuesday

Community Medicine

II

09.05.2024

Thursday

Medicine

I

10.05.2024

Friday

Medicine (Medicine, Dermatology, Psychiatry)

II

13.05.2024

Monday

Surgery (Surgery, Orthopedics)

I

14.05.2024

Tuesday

Surgery (Surgery, Ophthalmology, ENT)

II

PRACTICAL SCHEDULE

16.05.2024

Thursday

Community Medicine

17.05.2024

Friday

Medicine

18.05.2024

Saturday

Obstetrics & Gynecology

20.05.2024

Monday

Paediatrics

21.05.2024

Tuesday

Surgery

Candidates must have their Admit Card and Identity Card to enter the examination hall. Students are urged to stay informed about the latest updates by checking the Examination Section’s official website under the “STUDENT TAB” as mentioned in the schedule. It is advised that candidates visit the website regularly, the notice stated.

All India Institute of Medical Sciences, also known as AIIMS Delhi, is a globally acclaimed public medical research university and hospital based in New Delhi, India. The AIIMS Act, of 1956 govern the institute and operates autonomously under the Ministry of Health and Family Welfare.

To view the official notice, click the link below

Powered by WPeMatico

ICMR Invites Applications For training course on Medical Genetics in Reproductive and Child Health, MBBS, MD, MS, DM, MCh doctors can apply

New Delhi- The Indian Council of Medical Research (ICMR), is set to conduct a 4-week training course on “Medical Genetics in Reproductive and Child Health.” The program is sponsored by the Department of Health Research (DHR) and will take place at ICMR-NIRRCH in Mumbai from 3 to 28 June 2024. In this regard, ICMR has released an advertisement giving details of a 4-week DHR-sponsored training course.

ELIGIBILITY

1 Indian citizens with MBBS/MD/MS/DM or MCH holding regular positions are eligible to apply. Candidates from North-East and semi-urban/rural regions of India are encouraged to apply.

2 Candidates in service should forward their applications through the proper channels and upload an NOC from the Head of the Institution along with their application.

Eligible candidates can register themselves through the link given in the advertisement by April 25, 2024. After registration, selected candidates will receive an email confirmation by April 30, 2024. Although there is no fee for registration but however a refundable deposit of Rs 2000/- will be collected from the participants.

Besides, accommodation will also be provided to the participants on request at a nominal cost. For any further queries, candidates can contact through email, which is mentioned in the advertisement.

KEY HIGHLIGHTS

The objective of the program is to introduce existing technologies for genetic testing and their utilities, diagnostic algorithms for genetic disorders affecting potential and child health, interpretation of genetic diagnostic reports and genetic counselling.

ICMR-National Institute for Research in Reproductive and Child Health (ICMR-NIRRCH) located in Parel, Mumbai is a premier institute which conducts clinical, basic, operational and implementation research on different aspects of reproductive and child health. This DHR course is being organized by the Genetic Research Centre, ICMRNIRRCH. This course aims at imparting conceptual and technical know-how through a series of lectures, hands-on sessions and tutorials on the advances in clinical and laboratory genetics including research methodologies.

To view the advertisement, click the link below

Powered by WPeMatico

Show-cause notice to KEM Hospital for non-compliance with acts

Mumbai: Taking cognizance of alleged irregularities and violations of various acts, the state health department served a show cause to BMC-run King Edward Memorial (KEM) Hospital and asked to submit a report specifying the reasons why the institute should not be sealed.

Asking the hospital authorities why the government should not file a case against them, Dr Radhakishan Pawar, deputy director of health services clarified that the hospital has made repeated multiple violations in the past which could potentially put the patient’s health at risk. In addition, he also said that the hospital did not comply and paid no serious need to a previous notice. 

Also read- Violation Of PC PNDT Act: Licence Of Three Ultrasound Centres Suspended, Show Cause Notice Issued

The hospital considered one of the foremost in the state was served a notice earlier following a surprise inspection by the health department in December last year. During the inspection, it was found that the hospital allegedly violated the Assisted Reproductive Technology (Regulation) Act 2021 and Surrogacy (Regulation) Act, 2021; PC-PNDT Act; Bio-Medical Waste Rules 2016; and Maharashtra Nursing Home Registration Act 1949 and Regulations 2021.

The hospital was asked to provide a hard copy due to the significant deficiencies but allegedly responded to the notice via email. This promoted the health department to reinspect the facilities. On March 13, a team of officials visited the hospital and found that the hospital had not carried out any compliance.

Terming their action as “Wrong and Misleading”, Dr Pawar said, “The hospital submitted a letter to our last notice without any compliance. This will hamper the healthcare services provided to patients.”

In response, the state health department recently issued another show-cause notice asking them to complete the compliance on priority and submit the report. They have also asked the hospital to explain why it should not be sealed and should not be held legally accountable for breaking regulations.

Denying the allegations, Dr Madhur Rao, senior deputy medical administrator at KEM Hospital said the hospital has received satisfactory response from other departments and no such violation of acts have been made. 

As per the HT news report, Dr Rao said, “There have been no violations of any of the provisions of any of the statutes applicable to the hospital, including the Bombay Nursing Home Registration Act 1949 and Rules 2021; Medical Termination of Pregnancy Act 2021 and Rules and Regulations passed thereunder; PC-PNDT Act 1994 and the amendment in 2002 and Rules passed thereunder; ART (Regulation) Act 2021 and Surrogacy (Regulation) Act 2021; and BMW Rules 2016 etc. at KEM Hospital, Pune at any time.

The concerned appropriate authorities and various officials from the health department, Pune Municipal Corporation (PMC), and other departments have expressed their satisfaction and entered remarks as ‘satisfactory compliances’ during periodic inspections carried out under the provisions of the above-mentioned statutes at KEM Hospital, Pune from time to time.”

Also Read: KEM doctor swindled out of Rs 7.33 lakh by cyber fraudsters

Powered by WPeMatico

Lonza to buy large-scale biologics Vacaville site from Roche for USD 1.2 billion

Basel: Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, has announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, California (US) from Roche for USD 1.2 billion.

The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity to meet demand for commercial mammalian contract manufacturing from customers with existing commercial products, and molecules currently on the path to commercialization within the Lonza network. The Vacaville (US) facility currently has a total bioreactor capacity of around 330,000 liters. Under the agreement, approximately 750 Genentech employees at the Vacaville (US) facility will be offered employment by Lonza.

Demand for capacity for commercial biologics is expected to remain high across the CDMO industry as innovative new therapies reach approval. In this context, the acquisition of the Vacaville (US) site will provide Lonza’s customers with immediate access to significant new capacity in the United States, currently the world’s largest pharmaceutical market. It will also create a significant West Coast commercial manufacturing presence, complementing Lonza’s existing Biologics site on the East Coast, in Portsmouth (US), as well as its international network across Europe and Asia.

Lonza plans to invest approximately CHF 500 million in additional CAPEX to upgrade the Vacaville (US) facility and enhance capabilities to satisfy demand for the next generation of mammalian biologics therapies. The products currently manufactured at the site by Roche will be supplied by Lonza, with committed volumes over the medium term, phasing out over time as the site transitions to serve alternative customers.

Jean-Christophe Hyvert, President, Biologics, Lonza, commented, “The Vacaville site is a highly valuable strategic acquisition that will make capacity immediately available for our customers and unlock future growth for our Biologics division. It will support us in providing a commercialization path to existing customers and incremental large-scale commercial capacity to our partners. We have deep and long-standing industrial expertise in delivering commercial scale manufacturing services for our customers’ therapies. In combining this with the strong legacy of the Vacaville facility, its highly skilled colleague community and its proven track record on quality, we are excited to take our leading large-scale mammalian offering to its next chapter of growth.”

The transaction is expected to close in H2 2024, subject to customary closing conditions. Upon closing, the Vacaville (US) site will be integrated into Lonza’s Biologics division, joining a network of existing mammalian manufacturing sites in Visp (CH), Slough (UK), Singapore (SG), Portsmouth (US) and Porriño (ES).

As the transaction is expected to be accretive to sales growth, Lonza has updated its Mid-Term Guidance 2024 – 2028. Its sales growth range was set at 11 – 13% CAGR in CER1, and has now been updated to 12 – 15%. Mid-Term Guidance for CORE EBITDA margin and ROIC remains unchanged. The Mid-Term Guidance for the net debt / CORE EBITDA ratio and CAPEX trajectory also remain unchanged.

BofA Securities are acting as financial advisors to Lonza.

Read also: CDSCO Panel Grants Roche’s Protocol Amendment Proposal For Crovalimab study

Powered by WPeMatico